CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer by Seini Moimoi | Dec 5, 2023 | Portfolio News
Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer by Seini Moimoi | Nov 30, 2023 | Portfolio News
Nalu Medical, Inc., Announces Positive Results of US Spinal Cord Stimulation Clinical Study in Pain Physician Journal by Seini Moimoi | Nov 29, 2023 | Portfolio News
CG Oncology Announces Presentation of the First Phase 3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023 by Seini Moimoi | Nov 14, 2023 | Portfolio News
OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders by Seini Moimoi | Nov 7, 2023 | Portfolio News
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023 by Seini Moimoi | Nov 4, 2023 | Portfolio News
Endeavor BioMedicines Enters License Agreement With Hummingbird Bioscience For Worldwide Rights To HMBD-501, A Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC) by Seini Moimoi | Oct 19, 2023 | Portfolio News
Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by Seini Moimoi | Oct 17, 2023 | Portfolio News
Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference by Seini Moimoi | Oct 11, 2023 | Portfolio News
CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease by Seini Moimoi | Oct 9, 2023 | Portfolio News
